Immunoprecise Antibodies Ltd
NASDAQ:HYFT

Watchlist Manager
Immunoprecise Antibodies Ltd Logo
Immunoprecise Antibodies Ltd
NASDAQ:HYFT
Watchlist
Price: 2.03 USD 4.1% Market Closed
Market Cap: 93.7m USD

Operating Margin

-222.8%
Current
Declining
by 80.2%
vs 3-y average of -142.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-222.8%
=
Operating Income
CA$-32.9m
/
Revenue
CA$20.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-222.8%
=
Operating Income
$-32.9m
/
Revenue
CA$20.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Immunoprecise Antibodies Ltd
NASDAQ:HYFT
93.7m USD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
240.3B USD
Loading...
US
Danaher Corp
NYSE:DHR
171B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
38.3B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
41.1B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
278.3B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
39.6B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.5B USD
Loading...
US
Waters Corp
NYSE:WAT
23.6B USD
Loading...
No Stocks Found

Market Distribution

Lower than 89% of companies in the United States of America
Percentile
11th
Based on 14 112 companies
11th percentile
-222.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Immunoprecise Antibodies Ltd
Glance View

ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The company is headquartered in Austin, Texas. The company is advancing Bio-Native AI at the intersection of biology and computation. Its LENSai and HYFT platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. The core of its operations encompasses a diverse suite of proprietary technologies that aid in the exploration, discovery, and development of novel drugs and biologics. Integrated within its wet lab infrastructure is a diverse array of in silico technologies. As an end-to-end service provider of antibody discovery and development, its computational methodologies allow the Company to perform detailed and comprehensive evaluations across various stages of biologic discovery and development. The company is involved in antibody characterization studies, which encompass affinity measurements, epitope landscape profiling, and others.

HYFT Intrinsic Value
1.58 USD
Overvaluation 22%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-222.8%
=
Operating Income
CA$-32.9m
/
Revenue
CA$20.4m
What is Immunoprecise Antibodies Ltd's current Operating Margin?

The current Operating Margin for Immunoprecise Antibodies Ltd is -222.8%, which is below its 3-year median of -142.7%.

How has Operating Margin changed over time?

Over the last 3 years, Immunoprecise Antibodies Ltd’s Operating Margin has decreased from -179.9% to -222.8%. During this period, it reached a low of -225.6% on Dec 1, 2025 and a high of -69.6% on Apr 30, 2025.

Back to Top